Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 6/20 | 0.51 |
| ▸ | CLK1 | P49759 | 2/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | CLK3 | P49761 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30409556 | 0.82 | CDC7 (0.55) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL25185033 | 0.82 | CDC7 (0.55) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL2191369 | 0.75 | CDK2 (0.71) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL2191428 | 0.74 | GSK3B (0.53) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL12506933 | 0.72 | CDK2 (1.00) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL23558460 | 0.71 | CDC7 (0.45) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL23558475 | 0.71 | CDK2 (0.47) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL232173 | 0.71 | APP (0.50) | DYRK1BQPCTLCKBTKMEN1 | |
| SCHEMBL2461478 | 0.70 | GSK3B (0.60) | GSK3BCLK1CLK2CDK5DYRK1A | |
| SCHEMBL1706431 | 0.70 | QPCT (0.50) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | CDC7 1097/4885CCNE1 2505/4885CDK2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.